SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001737287-21-000013
Filing Date
2021-04-22
Accepted
2021-04-22 16:27:42
Documents
5
Period of Report
2021-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A allo-20210423xdef14axproxy.htm DEF 14A 665343
2 ceocompmix1.jpg GRAPHIC 27786
3 drafproxyimage12.jpg GRAPHIC 19512
4 otherneocompmix1.jpg GRAPHIC 33841
5 qualificationstable_4220211.jpg GRAPHIC 65141
  Complete submission text file 0001737287-21-000013.txt   868249
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38693 | Film No.: 21845159
SIC: 2836 Biological Products, (No Diagnostic Substances)
Office of Life Sciences